Can the weight-loss injection cause depression or anxiety?

Two drugs in the same class, in the same Korean dataset, produced a psychiatric signal in the same direction. That consistency is harder to dismiss than either result alone, and it still does not establish that the drugs are the cause.

Read the intervals, not just the numbers#

The semaglutide interval for depression runs from 1.51 to 7.74, which is very wide — 2,357 initiators is not many for an uncommon outcome, so the estimate is imprecise even though it is clearly above 1. The liraglutide figures are smaller and much tighter, resting on 6,953 initiators: 1.51 for depression, 1.68 for anxiety.

The other findings differ by drug#

Semaglutide's other strong association was gastrointestinal dysmotility or obstruction at 3.91, which follows directly from the known mechanism of slowing the stomach. Liraglutide instead showed hepatic impairment at 1.46, pancreatobiliary disorder at 1.33 and pancreatitis, cholangitis or cholelithiasis at 1.40.

The gallstone group is the one most likely to be misread. Rapid weight loss from any cause raises the risk of gallstones — it is why the same thing happens after bariatric surgery — so a hazard ratio of 1.40 in people losing weight quickly may be reporting the weight loss rather than the molecule.

What to do with this#

The authors themselves flag that semaglutide-associated vision impairment and liraglutide-associated hepatic impairment did not hold up across all sensitivity analyses, and ten outcomes tested across two drugs means twenty comparisons, so some positive results are expected by chance alone.

The reasonable position is the one they take: careful selection and monitoring rather than avoidance. If you have a history of depression or anxiety, that is worth raising before starting rather than after — both because it changes how closely you should be watched, and because it is the single factor most likely to make this signal relevant to you.